Get the latest news on Nymox Pharmaceutical stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on NYMXF performance

Latest Nymox Pharmaceutical Stock News | OTC:NYMXF | Benzinga

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

NYMOX PHARM CORP by Nymox Pharmaceutical Corp.

Nymox Pharmaceutical Corp

Press Releases

Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages

Health Care

Nymox Required to Resubmit Application to DKMA

Nymox Annual Report

Nymox Announces Filing of Annual Report

General

NYMOX Announces Trading Resumed and New Listing on OTCQB Market

NYMXF

Nymox Pharmaceutical

Comments

Nymox Pharmaceutical Stock News

News

Latest Nymox Pharmaceutical Stock News | OTC:NYMXF | Benzinga

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga